Literature DB >> 16273236

Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer.

Shinji Ozaki1, Satoshi Ikeda, Yasuyo Ishizaki, Takeshi Kurihara, Noriaki Tokumoto, Masahiko Iseki, Koji Arihiro, Tsuyoshi Kataoka, Mazazumi Okajima, Toshimasa Asahara.   

Abstract

Both cyclin D1 and c-myc are key molecules in breast cancer carcinogenesis, and their transcriptional level and stability are regulated through several signaling pathways, including the Wnt signaling pathway. We performed immunohistochemical and mutational analyses of Wnt signaling components to investigate the association of Wnt signaling alterations with breast cancer carcinogenesis using 49 surgically resected primary breast cancer samples. Positive staining of cyclin D1 and c-myc was observed in 55.1% and 30.6% of the 49 breast cancer samples, respectively. Aberrant cytoplasmic expression of beta-catenin, which indicates the existence of alterations in the Wnt signaling pathway, was observed in 38.8% of breast cancer samples, though no mutation was found in the beta-catenin and Axin 1 genes. Reduced expression of APC was observed in 34.7% of samples. Statistical analysis revealed strong correlations between overexpression of beta-catenin and that of cyclin D1 and c-myc (p=0.0001 and 0.0117, respectively). Furthermore, overexpression of beta-catenin was significantly correlated with reduced expression of APC (p=0.0127). Wnt signaling alterations were frequently observed in breast cancer from the results of beta-catenin immunohistochemistry, although no mutation in the components of the Wnt signaling pathway was found in the present study. Based on the statistical analyses, we speculated that reduced expression of APC leads to overexpression of beta-catenin, and aberrant expression of cyclin D1 and c-myc mainly depends on alterations in the Wnt signaling pathway in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16273236     DOI: 10.3892/or.14.6.1437

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  33 in total

1.  Expression and localization of E-cadherin and β-catenin in uterine carcinosarcoma.

Authors:  Izumi Nishimura; Yoshihiro Ohishi; Yoshinao Oda; Junji Kishimoto; Masafumi Yasunaga; Emi Okuma; Hiroaki Kobayashi; Norio Wake; Masazumi Tsuneyoshi
Journal:  Virchows Arch       Date:  2010-11-03       Impact factor: 4.064

Review 2.  Gap Junctions and Wnt Signaling in the Mammary Gland: a Cross-Talk?

Authors:  Sabreen F Fostok; Mirvat El-Sibai; Marwan El-Sabban; Rabih S Talhouk
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-07       Impact factor: 2.673

3.  The expression of VE-cadherin in breast cancer cells modulates cell dynamics as a function of tumor differentiation and promotes tumor-endothelial cell interactions.

Authors:  Maryam Rezaei; Jiahui Cao; Katrin Friedrich; Björn Kemper; Oliver Brendel; Marianne Grosser; Manuela Adrian; Gustavo Baretton; Georg Breier; Hans-Joachim Schnittler
Journal:  Histochem Cell Biol       Date:  2017-11-15       Impact factor: 4.304

4.  Association among the expression of β-catenin, cyclin D1 and estrogen receptor-β in human breast cancer.

Authors:  Liying Guo; Dilimina Yilamu; Liting Sun; Sha Liu; Fangjing Ma
Journal:  Exp Ther Med       Date:  2015-07-27       Impact factor: 2.447

5.  Simultaneous disruption of estrogen receptor and Wnt/β-catenin signaling is involved in methyl amooranin-mediated chemoprevention of mammary gland carcinogenesis in rats.

Authors:  Animesh Mandal; Deepak Bhatia; Anupam Bishayee
Journal:  Mol Cell Biochem       Date:  2013-12       Impact factor: 3.396

6.  Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians.

Authors:  Pooja Malhotra; Mumtaz Anwar; Neha Nanda; Rakesh Kochhar; Jai Dev Wig; Kim Vaiphei; Safrun Mahmood
Journal:  Tumour Biol       Date:  2013-03-24

7.  No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer.

Authors:  Ellen L Goode; Csilla Szabo; Ludmila Prokunina-Olsson; Robert A Vierkant; Zachary S Fredericksen; Francis S Collins; Kristin L White; Michele Schmidt; Brooke L Fridley; Fergus J Couch
Journal:  BMC Cancer       Date:  2009-09-04       Impact factor: 4.430

Review 8.  MYC in breast tumor progression.

Authors:  Yinghua Chen; Olufunmilayo I Olopade
Journal:  Expert Rev Anticancer Ther       Date:  2008-10       Impact factor: 4.512

9.  Evaluation of a variant in the transcription factor 7-like 2 (TCF7L2) gene and prostate cancer risk in a population-based study.

Authors:  Ilir Agalliu; Miia Suuriniemi; Ludmila Prokunina-Olsson; Bo Johanneson; Francis S Collins; Janet L Stanford; Elaine A Ostrander
Journal:  Prostate       Date:  2008-05-15       Impact factor: 4.104

10.  c-Myc affects mRNA translation, cell proliferation and progenitor cell function in the mammary gland.

Authors:  Tina Stoelzle; Patrick Schwarb; Andreas Trumpp; Nancy E Hynes
Journal:  BMC Biol       Date:  2009-09-28       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.